Xeris Biopharma Holdings, Inc.
HealthcareNASDAQ:XERS · NASDAQ Global Select
-$0.14 today
Vol 1.63M · Avg 1.63M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.0%
avg -36.3%
ROIC
8.9%
avg -48.0%
ROA
0.1%
avg -42.5%
Analysis
ROIC is currently the strongest return metric at 8.9% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Shannon | Chief Executive Officer & Director | $1.36M | — | 64 | $707,276.00 | 0.41% |
Kevin McCulloch | President & Chief Operating Officer | $913,527.00 | — | 62 | $1.78M | 1.03% |
Beth Hecht | Chief Legal Officer & Corporate Secretary | $817,367.00 | — | 62 | $1.18M | 0.68% |
Steven Pieper | Chief Financial Officer | $796,183.00 | — | 49 | $1.39M | 0.81% |
Anh Nguyen | Chief Medical Officer | $653,703.00 | — | 51 | $395,023.00 | 0.23% |
Kendal Korte | Senior Vice President of Human Resources | — | — | — | — | — |
Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | — | — | — | — | — |
Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$109,475.00
Sells
23
$4.46M
Net Sentiment
$4.35M
Net selling
Most Active
Hecht Beth
9 transactions
1–10 of 24
Analysis
Insiders reported 1 buys worth $109,475.00 and 23 sells worth $4.46M over the last 12 months. That adds up to net selling of $4.35M. Hecht Beth was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +135.9% | +42.5% (10yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +135.9% over three years. Forward estimates point to Revenue at +42.5% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.83B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages XERS?
Xeris Biopharma Holdings, Inc. (XERS) lists 8 active executives. The top listed executive is Anh Nguyen, Chief Medical Officer.
Are XERS insiders buying or selling?
Recent insider activity shows net buying of $4.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.